Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ruxolitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT02436135
What this trial is testing

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

Who this might be right for
Myelofibrosis
Gilead Sciences 10
Early research (Phase 1)Study completedNCT02613598
What this trial is testing

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Who this might be right for
Hodgkin's LymphomaLymphoma, Non-Hodgkin
University of Michigan Rogel Cancer Center 15
Testing effectiveness (Phase 2)UnknownNCT05569538
What this trial is testing

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Who this might be right for
Myelofibrosis
The University of Hong Kong 40
Testing effectiveness (Phase 2)Looking for participantsNCT06199427
What this trial is testing

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Who this might be right for
Inborn Errors of Immunity
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 100
Testing effectiveness (Phase 2)Study completedNCT02015208
What this trial is testing

Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
Sunnybrook Health Sciences Centre 13
Not applicableLooking for participantsNCT07673640
What this trial is testing

Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study

Who this might be right for
Non-Segmental Vitiligo (NSV)
ShanShan Li 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT03654768
What this trial is testing

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Who this might be right for
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
SWOG Cancer Research Network 81
Early research (Phase 1)Looking for participantsNCT06225310
What this trial is testing

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics 30
Early research (Phase 1)Study completedNCT02370706
What this trial is testing

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 15
Testing effectiveness (Phase 2)UnknownNCT04582604
What this trial is testing

Ruxolitinib and Decitabine for High Risk Hematological Malignancies

Who this might be right for
Peripheral Blood Stem Cell Transplantation
Chinese PLA General Hospital 60
Testing effectiveness (Phase 2)Study completedNCT01392443
What this trial is testing

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Who this might be right for
Primary Myelofibrosis (MF)Post-Polycythemia Vera (PV) MFPost-Essential Thrombocythemia (ET) MF
Novartis Pharmaceuticals 120
Testing effectiveness (Phase 2)Ended earlyNCT04269850
What this trial is testing

Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Who this might be right for
Intestinal GVHD
St. Petersburg State Pavlov Medical University 2
Testing effectiveness (Phase 2)Looking for participantsNCT07340723
What this trial is testing

Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

Who this might be right for
GVHD,AcuteStem Cell Transplant Complications
Daihong Liu 168
Testing effectiveness (Phase 2)Active Not RecruitingNCT03674047
What this trial is testing

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Who this might be right for
Other Cancer
Massachusetts General Hospital 50
Not applicableStudy completedNCT03208803
What this trial is testing

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis

Who this might be right for
Myelofibrosis; Anemia
Centre Hospitalier Annecy Genevois 65
Testing effectiveness (Phase 2)Study completedNCT03697460
What this trial is testing

Topical Ruxolitinib Lichen Planus

Who this might be right for
Lichen Planus
Aaron R. Mangold 12
Testing effectiveness (Phase 2)Study completedNCT04581954
What this trial is testing

Inflammatory Signal Inhibitors for COVID-19 (MATIS)

Who this might be right for
CoronavirusCovid19Pneumonia
Imperial College London 185
Large-scale testing (Phase 3)Study completedNCT06238817
What this trial is testing

Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

Who this might be right for
Atopic Dermatitis
Incyte Corporation 241
Testing effectiveness (Phase 2)Ended earlyNCT02120417
What this trial is testing

Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Incyte Corporation 149
Large-scale testing (Phase 3)WithdrawnNCT05219864
What this trial is testing

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

Who this might be right for
Hand Eczema
Incyte Corporation
Next Page